QL-S2309

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameQL-S2309
Drug Alias NameQLS2309QLS-2309
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD70Natural cytotoxicity triggering receptor 1 agonistsLow affinity immunoglobulin gamma Fc region receptor III-A agonists
TargetsCD70 antigenNatural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A